XML 31 R21.htm IDEA: XBRL DOCUMENT
v3.25.1

Common Stock, Stock Options and Warrants (Tables) | 6 Months Ended
--- | ---
Mar. 31, 2025
Common Stock, Stock Options and Warrants [Abstract] |
Schedule of Option Activity Under Our Stock Option Plans | A summary of option activity under our stock option plans (excluding the NoveCite and Citius Oncology Stock Plans) is presented below:
|  | Option Shares |  |  | Weighted- Average Exercise Price |  |  | Weighted- Average Remaining Contractual Term |  | Aggregate Intrinsic Value |
Outstanding at September 30, 2024 |  |  | 656,084 |  |  | $ | 36.41 |  |  | 7.26 years |  | $ | 0.00 |
Granted |  |  | 185,000 |  |  |  | 9.50 |  |  |  |  |  |  |
Exercised |  |  | - |  |  |  | - |  |  |  |  |  |  |
Forfeited or expired |  |  | - |  |  |  | - |  |  |  |  |  |  |
Outstanding at March 31, 2025 |  |  | 841,084 |  |  | $ | 30.49 |  |  | 7.39 years |  | $ | 0.00 |
Exercisable at March 31, 2025 |  |  | 511,018 |  |  | $ | 40.41 |  |  | 6.36 years |  | $ | 0.00 |
A summary of option activity under the Citius Oncology stock plans is presented below:
|  | Shares |  |  | Weighted- Average Exercise Price |  |  | Weighted- Average Remaining Contractual Term |  | Aggregate Intrinsic Value |
Outstanding at September 30, 2024 |  |  | 12,750,000 |  |  | $ | 2.15 |  |  | 8.78 years |  | $ | 0.00 |
Granted |  |  | 5,750,000 |  |  |  | 1.07 |  |  |  |  |  |  |
Forfeited |  |  | — |  |  |  |  |  |  |  |  |  |  |
Outstanding at March 31, 2025 |  |  | 18,500,000 |  |  | $ | 1.81 |  |  | 8.72 years |  | $ | — |
Exercisable at March 31, 2025 |  |  | 5,135,417 |  |  | $ | 2.06 |  |  | 8.39 years |  | $ | — |
Schedule of Exercise of Outstanding Warrants | The Company has reserved 4,254,478 shares of common stock for the exercise of outstanding warrants. The following table summarizes the warrants outstanding at March 31, 2025:
|  | Exercise price |  |  | Number |  |  | Expiration Dates
August 2018 Offering Investors |  | $ | 28.75 |  |  |  | 156,863 |  |  | August 14, 2025
August 2018 Offering Agent |  |  | 39.84 |  |  |  | 7,576 |  |  | August 8, 2025
April 2019 Offering Investors |  |  | 35.50 |  |  |  | 51,780 |  |  | April 5, 2025
April 2019 Offering Agent |  |  | 48.28 |  |  |  | 9,605 |  |  | April 5, 2025
September 2019 Offering Investors |  |  | 19.25 |  |  |  | 111,732 |  |  | September 27, 2025
September 2019 Offering Underwriter |  |  | 27.97 |  |  |  | 7,774 |  |  | September 27, 2025
February 2020 Exercise Agreement Agent |  |  | 31.88 |  |  |  | 5,555 |  |  | August 19, 2025
May 2020 Offering Investors |  |  | 25.00 |  |  |  | 66,824 |  |  | November 18, 2025
May 2020 Placement Agent |  |  | 33.20 |  |  |  | 6,226 |  |  | May 14, 2025
August 2020 Underwriter |  |  | 32.81 |  |  |  | 8,079 |  |  | August 10, 2025
January 2021 Offering Investors |  |  | 30.78 |  |  |  | 123,648 |  |  | July 27, 2026
January 2021 Offering Agent |  |  | 40.44 |  |  |  | 14,065 |  |  | July 27, 2026
February 2021 Offering Investors |  |  | 42.50 |  |  |  | 823,211 |  |  | February 19, 2026
February 2021 Offering Agent |  |  | 47.03 |  |  |  | 100,256 |  |  | February 19, 2026
May 2023 Offering Investors |  |  | 37.50 |  |  |  | 500,000 |  |  | May 8, 2028
May 2023 Offering Agent |  |  | 37.50 |  |  |  | 35,000 |  |  | May 3, 2028
April 2024 Offering Investors |  |  | 18.75 |  |  |  | 857,143 |  |  | October 30, 2029
April 2024 Offering Agent |  |  | 21.875 |  |  |  | 60,000 |  |  | April 25, 2029
November 2024 Offering Investors |  |  | 6.25 |  |  |  | 480,000 |  |  | November 18, 2029
November 2024 Offering Agent |  |  | 7.8125 |  |  |  | 33,600 |  |  | November 15, 2029
January 2025 Offering Investors |  |  | 3.91 |  |  |  | 743,496 |  |  | January 8, 2030
January 2025 Offering Agent |  |  | 5.0438 |  |  |  | 52,045 |  |  | January 7, 2030
|  |  |  |  |  |  | 4,254,478 |  |  |
Schedule of Common Stock Reserved for Future Issuances | A summary of common stock reserved for future issuances by the Company excluding all subsidiaries as of March 31, 2025 is as follows:
Stock plan options outstanding |  |  | 841,084 |
Stock plan shares available for future grants |  |  | 118,000 |
Warrants outstanding |  |  | 4,254,478 |
Total |  |  | 5,213,562 |

X
- Definition Summary of common stock reserved for future issuances. + References No definition available. + Details
Name: | ctxr_ScheduleOfCommonStockReservedForFutureIssuancesTableTextBlock
Namespace Prefix: | ctxr_
Data Type: | dtr:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details
Name: | us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_StockholdersEquityNoteAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration